Esclerose Múltipla

termo de indexação original: Multiple Sclerosis

O acervo do Cannabis Indica reúne 276 estudos científicos que tocam a condição Esclerose Múltipla, publicados entre 1981 e 2024. Pela leitura automatizada, 229 (83%) foram classificados como favoráveis, 33 (12%) como inconclusivos e 14 (5%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (140 estudos), seguido de ensaio clínico duplo-cego (39). Os compostos mais presentes são THC:CBD Farmacêutico, Tetraidrocanabinol (THC) e THC Farmacêutico. Aparece com frequência ao lado de Dor, Inflamação e Dor — Crônica.

Estudos indexados: 276
Período coberto: 1981–2024
Favoráveis: 229 · 83%
Inconclusivos: 33 · 12%
Desfavoráveis: 14 · 5%
Termo original: Multiple Sclerosis

O acervo em números

Tipo de estudo

Metanálise140

Ensaio Clínico Duplo-Cego39

Ensaio Clínico35

Estudo em Animais28

Metanálise Clínica24

Estudo Laboratorial10

Direção do resultado

Favorável229

Inconclusivo33

Desfavorável14

Por década

1980s3

1990s4

2000s39

2010s118

2020s112

Aparece junto com

Dor80 Inflamação50 Dor — Crônica47 Doenças Neurodegenerativas36 Epilepsia33 Doença de Alzheimer31 Câncer29 Ansiedade29

276 estudos

Filtrar e buscar no acervo →

2024
Application of the Bayesian network theory in clinical trial data: Severity shift in spasticity numeric rating scale in patients with multiple sclerosis
FavorávelMetanálise ClínicaTHC:CBD Farmacêutico
2024
Clinical outcome analysis of patients with multiple sclerosis - Analysis from the UK Medical Cannabis Registry
FavorávelMetanáliseQualidade de Vida
2024
Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial
InconclusivoEnsaio ClínicoDor Dor — Crônica Doenças Neurodegenerativas Tetraidrocanabinol (THC)Canabinoide Sintético (não especificado)+2
2024
Δ9-Tetrahydrocannabinol (THC): A Critical Overview of Recent Clinical Trials and Suggested Guidelines for Future Research
FavorávelMetanálise ClínicaDor Dependência Química Dependência — Cannabis Tetraidrocanabinol (THC)THC Farmacêutico+13
2023
Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial
InconclusivoEnsaio Clínico Duplo-CegoDor Dor — Crônica Dor — Neuropatia Periférica Canabinoide Sintético (não especificado)+2
2023
Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials
FavorávelMetanálise ClínicaTHC:CBD Farmacêutico
2023
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
InconclusivoMetanáliseDor Câncer Inflamação Anandamida (AEA)Endocanabinoide (não especificado)+26
2023
Medical Cannabis Received by Patients According to Qualifying Condition in a US State Cannabis Program: Product Choice, Dosing, and Age-Related Trends
FavorávelMetanáliseDor Câncer Dor — Crônica THC Farmacêutico CBD Farmacêutico+16
2023
Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials
FavorávelMetanáliseTHC:CBD Farmacêutico
2023
Therapeutic effect of cannabidiol on myocardial arachidonic acid content in various lipid fractions in a rat model of obesity
FavorávelEstudo em AnimaisInflamação Doenças Cardiovasculares (DCV)Estresse Oxidativo Endocanabinoide (não especificado)+3
2023
Use of non-medical cannabis in epilepsy: A scoping review
InconclusivoMetanáliseEpilepsia Doença de Alzheimer Epilepsia — Síndrome de Dravet CBD Farmacêutico+2
2022
A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment
FavorávelMetanáliseDor Câncer Ansiedade Anandamida (AEA)Tetraidrocanabinol (THC)+25
2022
A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis
DesfavorávelMetanálise ClínicaTHC:CBD Farmacêutico
2022
A systematic review of the effects of cannabis on cognition in people with multiple sclerosis
InconclusivoMetanáliseDisfunção Cognitiva
2022
Botanically-Derived Δ 9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis
FavorávelEstudo LaboratorialTHC:CBD Farmacêutico
2022
Cannabinoids in rheumatology: Friend, foe or a bystander?
InconclusivoMetanáliseDor Dor — Crônica Epilepsia Anandamida (AEA)Tetraidrocanabinol (THC)+19
2022
Cannabinoids in the Orthopedic Setting: A Literature Review
DesfavorávelMetanáliseDor Dor — Crônica Dependência — Opioides+6
2022
Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis
InconclusivoMetanálise ClínicaCâncer Ansiedade Depressão Canabinoide Sintético (não especificado)THC Farmacêutico+5
2022
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
InconclusivoMetanálise ClínicaDor Dor — Crônica Psicose THC Farmacêutico THC:CBD Farmacêutico+1
2022
Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug
FavorávelMetanáliseDor Câncer Inflamação Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+18
2022
Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study
FavorávelEnsaio ClínicoInflamação Disfunção Cognitiva Doenças Neurodegenerativas THC:CBD Farmacêutico
2022
Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications
FavorávelMetanáliseDor Inflamação Ansiedade Anandamida (AEA)Palmitoiletanolamida (PEA)+16
2022
Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?
FavorávelMetanáliseDor Câncer Efeitos Adversos da Cannabis Anandamida (AEA)Endocanabinoide (não especificado)+19
2022
Effects of SativexⓇ on cognitive function in patients with multiple sclerosis: A systematic review and meta-analysis
FavorávelMetanálise ClínicaDisfunção Cognitiva THC:CBD Farmacêutico
2022
Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials
FavorávelMetanálise ClínicaDoença de Parkinson AVC Lesões da Medula Espinhal+1
2022
Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty
FavorávelMetanáliseInflamação Disfunção Cognitiva Doenças Neurodegenerativas Anandamida (AEA)Endocanabinoide (não especificado)+15
2022
Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story?
FavorávelMetanáliseInflamação Epilepsia Epilepsia — Síndrome de Dravet Tetraidrocanabinol (THC)Endocanabinoide (não especificado)+7
2022
Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap
FavorávelMetanálise ClínicaDor Dor — Crônica Disfunção Cognitiva Tetraidrocanabinol (THC)THC:CBD Farmacêutico+1
2022
Integration of Cannabis Extract Tetrahydrocannabinol:Cannabidiol in an Interdisciplinary Therapy Setting: A Case of Chronic Multilocular Pain Disorder
FavorávelMetanáliseDor Câncer Inflamação Tetraidrocanabinol (THC)+10
2022
Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies
DesfavorávelMetanáliseDor Câncer Inflamação Anandamida (AEA)THC Farmacêutico+14
2022
Medical cannabis use in Canadians with multiple sclerosis
FavorávelMetanálise
2022
Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination
FavorávelMetanáliseTetraidrocanabinol (THC)THC:CBD Farmacêutico+1
2022
Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders
FavorávelMetanáliseDor Inflamação Epilepsia Canabinoide Sintético (não especificado)Canabidiol Anormal (Abn-CBD)+6
2022
Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives
FavorávelMetanáliseDor Câncer Inflamação Anandamida (AEA)Endocanabinoide (não especificado)+20
2022
Pharmacological treatment of tremor in multiple sclerosis; a systematic review
InconclusivoMetanálise ClínicaDoenças Neurodegenerativas
2022
Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice
InconclusivoMetanáliseInflamação Doenças Neurodegenerativas Doença de Alzheimer Anandamida (AEA)Tetraidrocanabinol (THC)+7
2022
Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain: A Systematic Review and Meta-analysis
InconclusivoMetanálise ClínicaDor Dor — Neuropatia Periférica Tetraidrocanabinol (THC)THC Farmacêutico+1
2022
Systematic reviews of randomized controlled trials of cannabinoid products in chronic pain conditions and for symptoms associated with multiple sclerosis: what do they tell us?
InconclusivoMetanálise ClínicaDor Dor — Crônica Dor — Neuropatia Periférica+1
2022
The effect of medical cannabis on cognitive functions: a systematic review
DesfavorávelMetanálise ClínicaDor Câncer Efeitos Adversos da Cannabis THC:CBD Farmacêutico CBD Farmacêutico+11
2022
Therapeutic Potential of Cannabinoids on Tumor Microenvironment: A Molecular Switch in Neoplasia Transformation
InconclusivoMetanáliseDor Câncer Estresse Oxidativo Anandamida (AEA)Endocanabinoide (não especificado)+15
2022
Treatment of Ovarian Hyperstimulation Syndrome in a Mouse Model by Cannabidiol, an Angiogenesis Pathway Inhibitor
FavorávelEstudo em AnimaisDor Câncer Inflamação+16
2022
TRPV1: A Common Denominator Mediating Antinociceptive and Antiemetic Effects of Cannabinoids
FavorávelMetanáliseDor Inflamação Efeitos Adversos da Cannabis Anandamida (AEA)Endocanabinoide (não especificado)+18
2021
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019
InconclusivoMetanáliseDor Câncer Dor — Crônica THC Farmacêutico CBD Farmacêutico+9
2021
A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor
InconclusivoEnsaio Clínico Duplo-CegoDoença de Parkinson Distonia Tremor Essencial
2021
A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis
InconclusivoMetanáliseDor Ansiedade Dor — Crônica+1
2021
A systematic review of possible interactions for herbal medicines and dietary supplements used concomitantly with disease-modifying or symptom-alleviating multiple sclerosis drugs
InconclusivoMetanáliseEfeitos Adversos da Cannabis
2021
Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes
FavorávelMetanáliseInflamação Diabetes DII — Doença de Crohn Anandamida (AEA)Endocanabinoide (não especificado)+5
2021
Cannabidiol and Other Cannabinoids in Demyelinating Diseases
FavorávelMetanáliseAVC Traumatismo Cranioencefálico
2021
Cannabidiol for Mood Disorders: A Call for More Research
DesfavorávelMetanáliseDor Dor — Crônica Depressão+3
2021
Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action
FavorávelMetanáliseCâncer Epilepsia Doenças Neurodegenerativas+1
2021
Cannabinoid Quinones—A Review and Novel Observations
FavorávelMetanáliseCâncer Inflamação Estresse Oxidativo Canabinoides Sintéticos HU-x Canabinol (CBN)+6
2021
Cannabinoids and bladder symptoms in multiple sclerosis
FavorávelMetanáliseDor Ansiedade Dor — Crônica+4
2021
Cannabis and Autoimmunity: Possible Mechanisms of Action
FavorávelMetanáliseInflamação Artrite Síndrome do Intestino Irritável Anandamida (AEA)Endocanabinoide (não especificado)+10
2021
Cannabis Use among Older Persons with Arthritis, Cancer and Multiple Sclerosis: Are We Comparing Apples and Oranges?
FavorávelEnsaio ClínicoCâncer Insônia e Distúrbios do Sono Artrite+1
2021
Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses
FavorávelMetanáliseTHC:CBD Farmacêutico
2021
Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations
FavorávelMetanáliseDor Dor — Crônica Epilepsia THC Farmacêutico THC:CBD Farmacêutico+7
2021
Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics
InconclusivoMetanáliseAnsiedade Epilepsia TEPT
2021
Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity
FavorávelMetanáliseTHC:CBD Farmacêutico
2021
Emerging potential of cannabidiol in reversing proteinopathies
FavorávelMetanáliseDoença de Alzheimer Doença de Parkinson Doença de Huntington+1
2021
Emerging role of cannabinoids and synthetic cannabinoid receptor 1/cannabinoid receptor 2 receptor agonists in cancer treatment and chemotherapy-associated cancer management
FavorávelMetanáliseDor Câncer Ansiedade+4
2021
Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases
FavorávelMetanáliseInflamação DII — Doença Inflamatória Intestinal Estresse+1
2021
Genetic Variants of Fatty Acid Amide Hydrolase Modulate Acute Inflammatory Responses to Colitis in Adult Male Mice
FavorávelEstudo em AnimaisInflamação Ansiedade Artrite Anandamida (AEA)Endocanabinoide (não especificado)+6
2021
Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research
FavorávelMetanáliseDor Dependência Química Câncer+16
2021
Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review
FavorávelMetanáliseEncefalite e Mielite
2021
Impaired awareness: Why people with multiple sclerosis continue using cannabis despite evidence to the contrary
InconclusivoEnsaio Clínico
2021
Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience
FavorávelMetanáliseTHC:CBD Farmacêutico
2021
Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions
DesfavorávelMetanáliseDor Dependência Química Efeitos Adversos da Cannabis 2-Araquidonoilglicerol (2-AG)Canabinoide Sintético (não especificado)+24
2021
Neuroprotective Potential of Limonene and Limonene Containing Natural Products
FavorávelMetanáliseAnsiedade Epilepsia Doenças Neurodegenerativas+2
2021
Patterns of Medical Cannabis Use among Patients Diagnosed with Multiple Sclerosis
FavorávelMetanálise
2021
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition
FavorávelMetanáliseDor Inflamação Dor — Crônica Anandamida (AEA)Endocanabinoide (não especificado)+14
2021
Potent T cell-mediated anti-inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis
FavorávelEstudo LaboratorialEncefalite e Mielite Imunodeficiência por Trauma Endocanabinoide (não especificado)Canabinoide Sintético (não especificado)
2021
Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis
FavorávelEnsaio ClínicoTHC Farmacêutico THC:CBD Farmacêutico+1
2021
Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials
FavorávelMetanálise ClínicaDor Dor — Crônica Doenças Neurodegenerativas THC:CBD Farmacêutico+5
2021
Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports
FavorávelMetanáliseDor Dor — Crônica Doenças Neurodegenerativas THC:CBD Farmacêutico+1
2021
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
FavorávelMetanáliseTHC:CBD Farmacêutico
2021
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity
FavorávelEnsaio ClínicoTHC:CBD Farmacêutico
2021
The cannabinoid system and microglia in health and disease
FavorávelMetanáliseDor Inflamação Ansiedade Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+7
2021
The Role of Cannabidiol in Neurological Disorders
FavorávelMetanáliseDisfunção Cognitiva Doenças Neurodegenerativas Doença de Alzheimer+8
2021
The Utility of Delta-9-Tetrahydrocannibinol Therapy in a Multiple Sclerosis Patient with a Neoplastic Brain Lesion
FavorávelMetanáliseTHC:CBD Farmacêutico
2021
Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders
FavorávelMetanáliseCâncer Inflamação Diabetes+2
2021
Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases
FavorávelMetanáliseDiabetes Artrite Artrite — Reumatoide+1
2021
Treatment with Delta-9-tetrahydrocannabinol/cannabidiol in Multiple Sclerosis: Influence on the Autonomy Profile according to the International Classification of Functioning, Disability and Health
FavorávelMetanáliseTHC:CBD Farmacêutico
2020
A Scoping Review on Clinical Trials of Pain Reduction With Cannabis Administration in Adults
InconclusivoMetanálise ClínicaDor Dor — Crônica Dor — Aguda+3
2020
Cannabinoid CB2 Receptor Functional Variation (Q63R) Is Associated with Multiple Sclerosis in Iranian Subjects
FavorávelMetanálise
2020
Cannabinoids in multiple sclerosis: A neurophysiological analysis
FavorávelEnsaio ClínicoTHC:CBD Farmacêutico
2020
Cannabis and Inflammatory Mediators
DesfavorávelMetanáliseInflamação Efeitos Adversos da Cannabis
2020
Cannabis and multiple sclerosis
FavorávelMetanáliseTHC:CBD Farmacêutico
2020
Cannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study
FavorávelEnsaio ClínicoDor Dor — Crônica Náusea e Vômito Tetraidrocanabinol (THC)Canabinol (CBN)+3
2020
Cannabis use for symptom relief in multiple sclerosis: A cross-sectional survey of webinar attendees in the US and Canada
FavorávelMetanálise
2020
Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial
FavorávelEnsaio Clínico Duplo-CegoDependência Química Efeitos Adversos da Cannabis Dependência — Cannabis THC Farmacêutico THC:CBD Farmacêutico
2020
Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis
FavorávelMetanálise
2020
CBD Suppression of EAE Is Correlated with Early Inhibition of Splenic IFN-γ + CD8+ T Cells and Modest Inhibition of Neuroinflammation
FavorávelEstudo em AnimaisEncefalite e Mielite
2020
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis
FavorávelMetanáliseTHC:CBD Farmacêutico
2020
Discontinuing cannabis improves depression in people with multiple sclerosis: A short report
InconclusivoMetanálise
2020
Dose-dependent effect of cannabinoid WIN-55,212-2 on myelin repair following a demyelinating insult
FavorávelEstudo em AnimaisCanabinoides Sintéticos WIN-x
2020
Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis
FavorávelEstudo em AnimaisCanabinoide Sintético (não especificado)
2020
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study
FavorávelEnsaio ClínicoTHC:CBD Farmacêutico
2020
Gene Expression Analysis of Astrocyte and Microglia Endocannabinoid Signaling during Autoimmune Demyelination
FavorávelEstudo Laboratorial2-Araquidonoilglicerol (2-AG)
2020
Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study
FavorávelEnsaio ClínicoTHC:CBD Farmacêutico
2020
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
FavorávelMetanáliseInflamação Ansiedade Depressão Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+8
2020
Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review
FavorávelMetanáliseInflamação Doenças Neurodegenerativas Doença de Alzheimer Palmitoiletanolamida (PEA)+3
2020
Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review
FavorávelMetanálise
2020
Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology
FavorávelMetanáliseDor Depressão Dor — Neuropatia Periférica Tetraidrocanabinol (THC)THC Farmacêutico+6
2020
Phytocannabinoid-dependent mTORC1 regulation is dependent upon inositol polyphosphate multikinase activity
FavorávelEstudo LaboratorialCanabigerol (CBG)Ácido Canabidiólico (CBD-a)+1
2020
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial
FavorávelEnsaio Clínico Duplo-CegoDor Dor — Oncológica THC:CBD Farmacêutico
2020
The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis
FavorávelMetanálise ClínicaDor Dor — Neuropatia Periférica Dor — Polineuropatia Inflamatória
2020
The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms
FavorávelMetanáliseTHC:CBD Farmacêutico
2020
The effects of chronic Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) use on cerebral glucose metabolism in multiple sclerosis: a pilot study
InconclusivoMetanáliseDiabetes Síndrome Metabólica
2020
The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis
FavorávelEstudo em AnimaisCanabinoide Sintético (não especificado)
2020
The pharmacological case for cannabigerol (CBG)
FavorávelMetanáliseDoença de Parkinson DII — Doença Inflamatória Intestinal Doença de Huntington Canabigerol (CBG)
2020
The pharmacological effects of inhaled cannabis on pain in patients with multiple sclerosis: risks versus rewards
FavorávelMetanáliseDor Dor — Neuropatia Periférica
2020
Δ 9 -Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo
FavorávelEstudo em Animais2-Araquidonoilglicerol (2-AG)
2019
A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis
FavorávelEstudo em AnimaisEncefalite e Mielite Imunodeficiência por Trauma Palmitoiletanolamida (PEA)
2019
A Novel Standardized Cannabis sativa L. Extract and Its Constituent Cannabidiol Inhibit Human Polymorphonuclear Leukocyte Functions
FavorávelEstudo LaboratorialDor Inflamação Doenças Cardiovasculares (DCV)+7
2019
Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing
FavorávelEnsaio ClínicoTHC:CBD Farmacêutico
2019
Can we teach old drugs new tricks?-Repurposing of neuropharmacological drugs for inflammatory skin diseases
FavorávelMetanáliseInflamação Depressão Epilepsia+14
2019
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
FavorávelEstudo em AnimaisInflamação Doenças Priônicas Canabinoide Sintético (não especificado)
2019
Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?
FavorávelMetanáliseDiabetes Artrite Artrite — Reumatoide Endocanabinoide (não especificado)Canabinoide Sintético (não especificado)
2019
Cannabis and multiple sclerosis
FavorávelMetanálise
2019
Cannabis for Neuropathic Pain in Multiple Sclerosis—High Expectations, Poor Data
FavorávelMetanálise
2019
Cannabis-based product use in a multiple sclerosis cohort
FavorávelMetanálise
2019
Caring for people with multiple sclerosis who use cannabis for symptom control
FavorávelMetanálise
2019
Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome
FavorávelEstudo em AnimaisDesequilíbrio do Microbioma Encefalite e Mielite THC:CBD Farmacêutico Microbioma
2019
Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways
FavorávelEstudo em AnimaisTHC:CBD Farmacêutico
2019
Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis
DesfavorávelEnsaio ClínicoDisfunção Cognitiva
2019
Effects of Cannabis sativa extract on haloperidol-induced catalepsy and oxidative stress in the mice
FavorávelEstudo em AnimaisEstresse Oxidativo Doenças Neurodegenerativas Doença de Parkinson+2
2019
Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal
FavorávelMetanálise
2019
Illegal cannabis use is common among Danes with multiple sclerosis
FavorávelMetanálise
2019
Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis
FavorávelMetanáliseDor Câncer Náusea e Vômito+7
2019
Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials
FavorávelMetanáliseTetraidrocanabinol (THC)THC:CBD Farmacêutico
2019
Priority Considerations for Medicinal Cannabis-Related Research
FavorávelMetanáliseDor Câncer Ansiedade+16
2019
The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray)
FavorávelEnsaio ClínicoTHC:CBD Farmacêutico
2019
The use of cannabinoids for sleep: A critical review on clinical trials
FavorávelMetanáliseDor Dor — Crônica Insônia e Distúrbios do Sono Tetraidrocanabinol (THC)+1
2019
US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions
FavorávelMetanáliseDor Câncer Inflamação CBD Farmacêutico+16
2018
2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs.
FavorávelEstudo em Animais2-Araquidonoilglicerol (2-AG)Monoacilglicerol Lipase (MAGL)
2018
A Review of Herbal Therapy in Multiple Sclerosis
FavorávelMetanálise
2018
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
FavorávelMetanáliseDoença de Parkinson Doença de Huntington Tetraidrocanabinol (THC)THC:CBD Farmacêutico
2018
Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells
FavorávelEstudo em Animais
2018
Cannabidiol to Improve Mobility in People with Multiple Sclerosis
FavorávelMetanálise
2018
Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials.
FavorávelMetanálise Clínica
2018
Cannabinoids for Treatment of MS Symptoms: State of the Evidence
FavorávelMetanáliseTetraidrocanabinol (THC)
2018
Cannabis Therapeutics and the Future of Neurology
FavorávelMetanáliseCâncer Epilepsia Doenças Neurodegenerativas Tetraidrocanabinol (THC)Ácido Canabidiólico (CBD-a)+8
2018
Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis.
FavorávelEnsaio ClínicoTHC:CBD Farmacêutico
2018
Gut microbiota, cannabinoid system and neuroimmune interactions: New perspectives in multiple sclerosis
FavorávelMetanáliseInflamação Artrite DII — Doença Inflamatória Intestinal Endocanabinoide (não especificado)Microbioma+1
2018
Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.
FavorávelEstudo em AnimaisCanabinoide Sintético (não especificado)
2018
In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid
FavorávelEstudo LaboratorialInflamação Estresse Oxidativo Doenças Neurodegenerativas Canabigerol (CBG)+2
2018
Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's disease and Less Well-Known Diseases.
FavorávelMetanáliseDoenças Cardiovasculares (DCV)Doença de Alzheimer Autismo Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
2018
Medical use of cannabis: Italian and European legislation.
FavorávelMetanáliseDor Ansiedade Náusea e Vômito THC Farmacêutico THC:CBD Farmacêutico+9
2018
Multiple Sclerosis, Cannabis Use, and Clinical Disability: A Preliminary [18F]-Fluorodeoxyglucose Positron Emission Tomography Study
InconclusivoMetanáliseEfeitos Adversos da Cannabis Tetraidrocanabinol (THC)
2018
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study
FavorávelEnsaio ClínicoEfeitos Adversos da Cannabis Tetraidrocanabinol (THC)THC:CBD Farmacêutico
2018
Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol
FavorávelMetanáliseCâncer Câncer — Mama Câncer — Cérebro THC:CBD Farmacêutico CBD Farmacêutico+4
2018
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
FavorávelMetanálise ClínicaTetraidrocanabinol (THC)THC:CBD Farmacêutico
2018
Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
FavorávelEnsaio Clínico Duplo-CegoTetraidrocanabinol (THC)THC:CBD Farmacêutico
2018
Standardized cannabis in multiple sclerosis: a case report.
FavorávelMetanáliseTetraidrocanabinol (THC)Canabinol (CBN)
2018
Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms.
FavorávelMetanáliseDor Dor — Crônica Náusea e Vômito+2
2018
Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis
FavorávelMetanáliseTHC:CBD Farmacêutico
2018
Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship
FavorávelEnsaio ClínicoTetraidrocanabinol (THC)THC:CBD Farmacêutico
2018
THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study
FavorávelEnsaio ClínicoTetraidrocanabinol (THC)THC:CBD Farmacêutico
2018
The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
InconclusivoMetanálise
2018
The protective effects of β-caryophyllene on LPS-induced primary microglia M1/M2 imbalance: A mechanistic evaluation.
FavorávelEstudo LaboratorialInflamação Doença de Alzheimer
2018
The Risks and Benefits of Cannabis in the Dermatology Clinic.
FavorávelMetanáliseCâncer Câncer — Melanoma Acne+5
2018
The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report.
FavorávelMetanáliseDor Ansiedade Dor — Crônica+7
2018
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
FavorávelMetanáliseTetraidrocanabinol (THC)THC Farmacêutico+1
2018
Therapeutic Benefit of Smoked Cannabis in Randomized Placebo-Controlled Studies
InconclusivoMetanálise ClínicaDor Efeitos Adversos da Cannabis Doenças Cardiovasculares (DCV)Tetraidrocanabinol (THC)THC Farmacêutico+8
2018
Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis.
FavorávelMetanáliseAnandamida (AEA)Tetraidrocanabinol (THC)+10
2017
Big conductance calcium-activated potassium channel openers control spasticity without sedation
FavorávelEstudo em AnimaisEncefalite e Mielite Anandamida (AEA)Endocanabinoide (não especificado)+1
2017
Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis.
FavorávelMetanálise
2017
Cannabis and cognitive functioning in multiple sclerosis: The role of gender
DesfavorávelMetanáliseEfeitos Adversos da Cannabis Disfunção Cognitiva
2017
Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity
FavorávelMetanáliseTHC:CBD Farmacêutico
2017
Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
FavorávelEnsaio Clínico Duplo-CegoDor Inflamação Ansiedade THC Farmacêutico+4
2017
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis
FavorávelEnsaio Clínico Duplo-CegoDor Inflamação Dor — Neuropatia Periférica Tetraidrocanabinol (THC)Canabinoide Sintético (não especificado)
2017
iperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration
FavorávelEnsaio ClínicoAnsiedade Estresse Oxidativo THC:CBD Farmacêutico
2017
Medical cannabis: Another piece in the mosaic of autoimmunity?
FavorávelMetanáliseInflamação Diabetes Artrite+3
2017
Medical use of cannabis in Switzerland: analysis of approved exceptional licences.
FavorávelMetanáliseDor Dor — Crônica Lesões da Medula Espinhal Tetraidrocanabinol (THC)THC Farmacêutico
2017
Neurological Aspects Of Medical Use Of Cannabidiol
FavorávelMetanáliseEpilepsia Disfunção Cognitiva Doença de Alzheimer+4
2017
Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.
FavorávelEstudo em AnimaisDiabetes Artrite Artrite — Reumatoide Tetraidrocanabinol (THC)
2017
Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
FavorávelEstudo LaboratorialCanabinoide Sintético (não especificado)
2017
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
FavorávelMetanáliseTHC:CBD Farmacêutico
2017
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients
FavorávelEnsaio ClínicoDor Inflamação Dor — Crônica THC:CBD Farmacêutico+1
2017
Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges.
FavorávelMetanáliseArtrite HIV/AIDS Artrite — Reumatoide Anandamida (AEA)Tetraidrocanabinol (THC)+20
2017
The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations
FavorávelMetanáliseDor Inflamação Dor — Crônica Palmitoiletanolamida (PEA)+7
2017
Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis.
FavorávelMetanáliseTetraidrocanabinol (THC)THC:CBD Farmacêutico
2017
β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis
FavorávelEstudo em AnimaisDoenças Neurodegenerativas Encefalite e Mielite Canabinoides Sintéticos AM-x Canabinoides Sintéticos JWH-x
2016
A CB2-Selective Cannabinoid Suppresses T-cell Activities and Increases Tregs and IL-10
FavorávelEstudo LaboratorialInflamação AVC DII — Doença Inflamatória Intestinal Endocanabinoide (não especificado)Canabinoides Sintéticos O-x+5
2016
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
FavorávelMetanáliseTHC:CBD Farmacêutico
2016
Cannabinoids and autoimmune diseases: A systematic review
FavorávelMetanáliseInflamação Diabetes Síndrome do Intestino Irritável
2016
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
FavorávelMetanáliseTetraidrocanabinol (THC)THC:CBD Farmacêutico
2016
Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
FavorávelMetanáliseTetraidrocanabinol (THC)THC:CBD Farmacêutico
2016
Endocannabinoid System: A Multi-Facet Therapeutic Target.
FavorávelMetanáliseDoenças Cardiovasculares (DCV)Epilepsia Esquizofrenia Tetraidrocanabinol (THC)Canabinoide Sintético (não especificado)+11
2016
Endocannabionoid System In Neurological Disorders
FavorávelMetanáliseDoença de Alzheimer Doença de Parkinson Doença de Huntington
2016
Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis
FavorávelEnsaio ClínicoDor Inflamação Dor — Crônica THC:CBD Farmacêutico+4
2016
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity
FavorávelEnsaio ClínicoInsônia e Distúrbios do Sono THC:CBD Farmacêutico
2016
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis
FavorávelEnsaio Clínico Duplo-CegoDor Inflamação Dor — Crônica Anandamida (AEA)Palmitoiletanolamida (PEA)+2
2016
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper
FavorávelMetanáliseTHC:CBD Farmacêutico
2016
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice
FavorávelEnsaio ClínicoQualidade de Vida THC:CBD Farmacêutico
2016
THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
FavorávelMetanáliseTHC:CBD Farmacêutico
2016
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
FavorávelMetanálise
2016
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
FavorávelEnsaio ClínicoTetraidrocanabinol (THC)THC:CBD Farmacêutico
2016
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®
FavorávelEnsaio ClínicoDoenças Neurodegenerativas THC:CBD Farmacêutico
2015
Activity of liver enzymes in multiple sclerosis patients with Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention
FavorávelEnsaio Clínico Duplo-Cego
2015
Alteration of delta-6-desaturase (FADS2), secretory phospholipase-A2 (sPLA2) enzymes by Hot-nature diet with co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients
FavorávelEnsaio Clínico Duplo-CegoDieta
2015
Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?
FavorávelMetanáliseDoença de Parkinson Doença de Huntington
2015
Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials
FavorávelMetanálise ClínicaDor Dor — Crônica Dor — Neuropatia Periférica Tetraidrocanabinol (THC)+5
2015
Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review
FavorávelMetanálise ClínicaDor Dor — Crônica Dor — Neuropatia Periférica
2015
Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease
FavorávelMetanáliseInflamação Artrite Artrite — Reumatoide Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
2015
Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis
FavorávelEnsaio Clínico Duplo-CegoTHC:CBD Farmacêutico
2015
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis
DesfavorávelEnsaio Clínico Duplo-CegoInflamação Estresse Oxidativo Doenças Neurodegenerativas Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
2014
A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis.
FavorávelEstudo em AnimaisEncefalite e Mielite Canabinoide Sintético (não especificado)Canabinoides Sintéticos AM-x+3
2014
Cannabinoid mouth spray brought help to a severely spastic young man
FavorávelMetanálise
2014
Nabilone as an Adjunctive to Gabapentin for Multiple Sclerosis-Induced Neuropathic Pain: A Randomized Controlled Trial
FavorávelEnsaio Clínico Duplo-CegoDor Dor — Crônica Dor — Neuropatia Periférica Tetraidrocanabinol (THC)THC Farmacêutico
2014
Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes
FavorávelMetanálise ClínicaTetraidrocanabinol (THC)THC:CBD Farmacêutico
2014
Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology
FavorávelMetanálise ClínicaDor Epilepsia Doença de Parkinson THC Farmacêutico THC:CBD Farmacêutico+5
2014
The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC–MS/MS
DesfavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos do MDMA THC:CBD Farmacêutico Canabinol (CBN)
2014
The effect of cannabidiol on ischemia/reperfusion-induced ventricular arrhythmias: the role of adenosine A1 receptors
FavorávelEstudo em AnimaisDor Inflamação Doenças Cardiovasculares (DCV)Endocanabinoide (não especificado)+6
2013
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial
InconclusivoEnsaio Clínico Duplo-CegoDor Inflamação Dor — Crônica THC Farmacêutico+2
2012
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
InconclusivoEnsaio Clínico Duplo-CegoDor Dor — Crônica Dor — Neuropatia Periférica THC:CBD Farmacêutico+1
2012
An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics
FavorávelEnsaio ClínicoDor Câncer Ansiedade Endocanabinoide (não especificado)THC Farmacêutico+10
2012
Multiple sclerosis and extract of cannabis: results of the MUSEC trial
FavorávelEnsaio Clínico Duplo-CegoDor Insônia e Distúrbios do Sono
2012
Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
FavorávelEnsaio Clínico Duplo-CegoDor Câncer Náusea e Vômito THC Farmacêutico+3
2012
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
FavorávelEnsaio ClínicoPsicose THC:CBD Farmacêutico
2012
Smoked Cannabis for Spasticity in Multiple Sclerosis: A Randomized, Placebo-Controlled Trial
FavorávelEnsaio Clínico Duplo-CegoDistonia
2012
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
FavorávelMetanáliseDor Náusea e Vômito Dor — Neuropatia Periférica Tetraidrocanabinol (THC)THC Farmacêutico+4
2011
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)
FavorávelEnsaio ClínicoDor Ansiedade Dor — Crônica Anandamida (AEA)Endocanabinoide (não especificado)+8
2011
Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice
FavorávelEstudo em AnimaisTuberculose
2011
Targets of curcumin
FavorávelMetanáliseCâncer Inflamação Doenças Cardiovasculares (DCV)Cúrcuma+16
2011
The multiplicity of action of cannabinoids: implications for treating neurodegeneration
FavorávelMetanáliseDoenças Cardiovasculares (DCV)Doenças Neurodegenerativas Doença de Parkinson Endocanabinoide (não especificado)Canabinoide Sintético (não especificado)+3
2010
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
FavorávelEnsaio Clínico Duplo-CegoTHC:CBD Farmacêutico
2010
Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders
FavorávelMetanáliseDoença de Alzheimer Doença de Parkinson Doença de Huntington Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
2010
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis
InconclusivoEnsaio Clínico Duplo-CegoTHC:CBD Farmacêutico
2010
The Endocannabinoid System In The Inflammatory And Neurodegenerative Processes Of Multiple Sclerosis And Of Amyotrophic Lateral Sclerosis
FavorávelMetanáliseEsclerose Lateral Amiotrófica (ELA)Endocanabinoide (não especificado)
2009
A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules.
FavorávelEstudo em AnimaisCanabinoides Sintéticos WIN-x
2009
Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
FavorávelEnsaio Clínico Duplo-CegoDor Tetraidrocanabinol (THC)THC:CBD Farmacêutico
2009
Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis
DesfavorávelEnsaio ClínicoTHC:CBD Farmacêutico
2009
Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
FavorávelEnsaio Clínico Duplo-CegoTetraidrocanabinol (THC)THC:CBD Farmacêutico
2009
Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review
FavorávelMetanálise Clínica
2008
Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis.
FavorávelEnsaio ClínicoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
2008
Current Status of Cannabis Treatment of Multiple Sclerosis with an Illustrative Case Presentation of a Patient with MS, Complex Vocal Tics, Paroxysmal Dystonia, and Marijuana Dependence Treated with Dronabinol.
FavorávelMetanáliseDependência Química Dependência — Cannabis Tetraidrocanabinol (THC)THC Farmacêutico
2008
Targeting the endocannabinoid system: to enhance or reduce?
FavorávelMetanáliseDor Câncer Inflamação Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+18
2007
Cannabinoids in health and disease
FavorávelMetanáliseDor Inflamação Dependência — Cannabis Anandamida (AEA)Tetraidrocanabinol (THC)+25
2007
Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
FavorávelEnsaio ClínicoDor Insônia e Distúrbios do Sono Dor — Neuropatia Periférica THC:CBD Farmacêutico+3
2007
Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors.
FavorávelEstudo em AnimaisCanabinoides Sintéticos WIN-x Canabinoides Sintéticos CP-x
2007
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
FavorávelEnsaio ClínicoDor Dor — Síndrome da Dor Central Tetraidrocanabinol (THC)THC:CBD Farmacêutico
2007
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis
FavorávelEnsaio Clínico Duplo-CegoTetraidrocanabinol (THC)
2007
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.
FavorávelEnsaio ClínicoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+5
2006
Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection
FavorávelEstudo em AnimaisEncefalite e Mielite 2-Araquidonoilglicerol (2-AG)
2006
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
InconclusivoEnsaio ClínicoTHC:CBD Farmacêutico
2006
Multiple sclerosis may disrupt endocannabinoid brain protection mechanism
FavorávelMetanáliseInflamação Doenças Neurodegenerativas Traumatismo Cranioencefálico Anandamida (AEA)Endocanabinoide (não especificado)+1
2006
Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
FavorávelMetanáliseDor Dor — Neuropatia Periférica Tetraidrocanabinol (THC)THC:CBD Farmacêutico
2006
The cannabinergic system as a target for anti-inflammatory therapies.
FavorávelMetanáliseDoenças Cardiovasculares (DCV)Diabetes Artrite Endocanabinoide (não especificado)Canabinoide Sintético (não especificado)+4
2006
The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).
FavorávelEnsaio Clínico Duplo-CegoInfecção Urinária
2006
Therapeutic action of cannabinoid on axonal injury induced by peroxynitrite.
FavorávelEstudo em AnimaisTraumatismo Cranioencefálico Canabinoides Sintéticos HU-x
2005
[Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication]
FavorávelEnsaio Clínico Duplo-CegoDor Dor — Síndrome da Dor Central THC Farmacêutico
2005
Cannabinoid influence on cytokine profile in multiple sclerosis
InconclusivoEnsaio Clínico Duplo-CegoTetraidrocanabinol (THC)
2005
Cannabinoids in multiple sclerosis -- therapeutically reasonable?
FavorávelMetanálise
2005
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
FavorávelEnsaio Clínico Duplo-CegoDor Insônia e Distúrbios do Sono Dor — Síndrome da Dor Central Tetraidrocanabinol (THC)THC:CBD Farmacêutico
2005
Sativex for the management of multiple sclerosis symptoms.
FavorávelMetanáliseTetraidrocanabinol (THC)THC:CBD Farmacêutico
2005
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series
FavorávelEnsaio Clínico Duplo-CegoTHC Farmacêutico
2004
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis
FavorávelEnsaio ClínicoDor Incontinência Urinária Tetraidrocanabinol (THC)
2004
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo- controlled study on 160 patients
FavorávelEnsaio Clínico Duplo-CegoTetraidrocanabinol (THC)
2004
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
FavorávelEnsaio Clínico Duplo-CegoTHC Farmacêutico
2004
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study
InconclusivoEnsaio Clínico Duplo-CegoTetraidrocanabinol (THC)
2004
The effect of cannabis on tremor in patients with multiple sclerosis
InconclusivoEnsaio Clínico Duplo-Cego
2003
A Preliminary Controlled Study To Determine Whether Whole-plant Cannabis Extracts Can Improve Intractable Neurogenic Symptoms
FavorávelEnsaio Clínico Duplo-CegoDor Dor — Crônica Lesões da Medula Espinhal+1
2003
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
InconclusivoEnsaio Clínico Duplo-CegoDoenças Neurodegenerativas
2003
Cannabis Use as Described by People with Multiple Sclerosis.
FavorávelMetanálise
2002
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
DesfavorávelEnsaio Clínico Duplo-Cego
2002
The palmitoylethanolamide family: a new class of anti-inflammatory agents?
FavorávelMetanáliseDor Inflamação Dor — Crônica Anandamida (AEA)Palmitoiletanolamida (PEA)
2000
Cannabinoids Control Spasticity And Tremor In A Multiple Sclerosis Model.
FavorávelEstudo em AnimaisCanabinoides Sintéticos WIN-x Canabinoides Sintéticos SR-x+2
2000
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes.
FavorávelEstudo LaboratorialDisfunção Cognitiva Doença de Alzheimer Doença de Parkinson
1998
The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway.
FavorávelEstudo em AnimaisEncefalite e Mielite Anandamida (AEA)Outros Compostos Relacionados
1997
The Perceived Effects Of Smoked Cannabis On Patients With Multiple Sclerosis.
FavorávelMetanálise
1995
Nabilone In The Treatment Of Multiple Sclerosis.
FavorávelEnsaio ClínicoTetraidrocanabinol (THC)THC Farmacêutico
1993
Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers
DesfavorávelEnsaio Clínico Duplo-CegoTetraidrocanabinol (THC)
1989
Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.
FavorávelMetanálise
1988
Delta-9-THC in the Treatment of Spasticity Associated with Multiple Sclerosis
FavorávelEnsaio Clínico Duplo-CegoTetraidrocanabinol (THC)
1981
Treatment of human spasticity with delta 9-tetrahydrocannabinol.
FavorávelEnsaio Clínico Duplo-CegoAVC Lesões da Medula Espinhal

Continue por aqui

Canabinoides e compostos

THC:CBD Farmacêutico 94 Tetraidrocanabinol (THC) 56 THC Farmacêutico 36 Anandamida (AEA) 34 2-Araquidonoilglicerol (2-AG) 30 Endocanabinoide (não especificado) 28 Canabinoide Sintético (não especificado) 24 CBD Farmacêutico 17

Sistemas do corpo

Sistema Nervoso 145 Saúde Mental e Emocional 11 Sistema Digestório 5 Sistema Esquelético 5 Sistema Urinário 4 Sistema Endócrino 3

Perguntas frequentes

Quantos estudos sobre esclerose múltipla estão indexados no acervo?

São 276 estudos, publicados entre 1981 e 2024. O acervo inteiro tem 7.640 registros.

Que tipos de estudo predominam?

Metanálise: 140 · Ensaio Clínico Duplo-Cego: 39 · Ensaio Clínico: 35 · Estudo em Animais: 28 · Metanálise Clínica: 24 · Estudo Laboratorial: 10. A classificação segue o desenho declarado na fonte.

O que significa a classificação de resultado?

É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 229 favoráveis, 33 inconclusivos e 14 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Esclerose Múltipla — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/esclerose-multipla/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Esclerose Múltipla — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/esclerose-multipla/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.